Pipeline Overview*
Pipeline Overview*
| Drug** | Indication | Pre-clinical | Phase 1/2 | Phase 3 | Approved | |
|---|---|---|---|---|---|---|
| Talicia® | H. pylori infection*** | Approved by U.S. FDA November 2019 |
||||
| RHB-104 | Crohn's disease | Positive top-line results from Phase 3 MAP US study |
||||
| RHB-204 | NTM infections | Pivotal Phase 3 study planned |
||||
| RHB-102 (Bekinda®) |
Gastroenteritis & gastritis | Positive results from Phase 3 U.S. study |
||||
| IBS-D | Positive results from Phase 2 U.S. study |
|||||
| RHB-106 | Bowel cleanser |  WW rights licensed to Salix Pharmaceuticals |
||||
| ABC294640 (Yeliva®) |
Multiple indications | Cholangiocarcinoma and other indications |
||||
| RHB-107 | Oncology/GI | Completed multiple clinical studies |
||||
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies**Bekinda® (RHB-102) and Yeliva® (ABC294640) are proposed tradenames which are subject to FDA review and approval. ***Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: here
